Abstract 2120
Background
Hyperprogressive disease (HPD) is a new pattern of tumor response described with immune checkpoint inhibitors (ICI), characterized by a sharp acceleration of tumor growth after the administration of the treatment. Several definitions based on clinical and/or radiological criteria have been proposed, although different factors limit their applicability. The mechanistic rationale has still not been elucidated. Our group has monitored lymphocyte populations in peripheral blood from non-small cell lung cancer patients (NSCLC) under ICI treatment with flow cytometry, and correlated the findings with HPD.
Methods
41 NSCLC patients treated with ICI after progression to ≥ 1 lines of chemotherapy for advanced disease have been included. We analyzed lymphocyte subpopulations from peripheral blood samples obtained immediately before the administration of the 1st and 2nd cycle of ICI. The expression of the following markers has been considered: CD3, CD4, CD8, CD27, CD28, CD45RA, CD62L, PD1. We correlated the findings with HPD as defined by TGR (Champiat S, 2017) and TGKR (Sâada-Bouzid E, 2017).
Results
Overall response rate (ORR) was 23.8%, and disease control rate (DCR) was 31%. 10 patients (23.8%) presented HPD by TGKR, and 7 patients (16.7%) by TGR. 9 patients (21.4%) could not be evaluated for HPD, mainly due to progression by non-measurable disease or death before further radiological. Median progression free survival (mPFS) was 6 weeks for HPD by TGR and 6.3 weeks by TGKR. We found that the mean proportion of post/pre-treatment LT CD4+ CD27- CD28- was significantly higher for HPD patients (1.86; CI95% 1.14 to 2.58 than non-HPD (1.09; CI95% 0.89 to 1.30) (p = 0.0033). An increase > 30% in LT CD4+/CD27-/CD28- after the first cycle of immunotherapy was associated with fast progression (ORR 0%, mPFS 6 weeks [CI95% 5.8 to 6.2], 8-weeks PFS 0%). Cohen’s kappa between HPD by TGR and by LT was 0.503 (p = 0.004).
Conclusions
HPD as defined by LT CD4+ CD27- CD28- burst > 30% might complement the limitations of radiological criteria as it does not require the evaluation of the tumor kynetics previous to the beggining of immunotherapy, nor it is influenced by non-measurable disease or tumor burden.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AECC, ISCIII.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2494 - CAR-T Nursing Education at a UK Specialist Cancer Hospital
Presenter: Rose Ellard
Session: Poster Display session 3
Resources:
Abstract
2438 - Professional Quality of Life, Perceived Stress and Psychological Resistance Levels of Oncology-Hematology Nurses and the Factors Affecting
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
3541 - Representation of cancer survivors’ preferences in policies for supportive care: Implications for oncology nursing
Presenter: Samantha Mayo
Session: Poster Display session 3
Resources:
Abstract
5093 - Vaginal moisturizing post PDR-Pulse Dose Rate Brachytherapy.
Presenter: Pilar Fernández
Session: Poster Display session 3
Resources:
Abstract
1066 - The stomized, chemo and radiotreated patient vs untreated patient: complications and comparison with data literature
Presenter: Cristoforo Ferrero
Session: Poster Display session 3
Resources:
Abstract
1724 - Evaluating the role of clinical nurse specialist
Presenter: Anita Zeneli
Session: Poster Display session 3
Resources:
Abstract
3753 - Role of the Advanced Practice Nurse (APN) in a Functional Unit for Lung cancer at the Catalan Institute of Oncology
Presenter: Isabel Brao
Session: Poster Display session 3
Resources:
Abstract
2676 - A bottom-up approach for prioritising the scientific activities of the Italian Association of Cancer Nurses (AIIAO): rationale and topic identification
Presenter: Valentina Biagioli
Session: Poster Display session 3
Resources:
Abstract
575 - Investigating quality of care for people with cancer and dementia
Presenter: Naomi Farrington
Session: Poster Display session 3
Resources:
Abstract
5578 - Two years of BRCA1 and BRCA2 somatic External Quality Assessment with Gen&tiss Tiss scheme in France
Presenter: Kelly Dufraing
Session: Poster Display session 3
Resources:
Abstract